No Data
No Data
Needham Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $30
Promising Upside for Bicycle Therapeutics: Buy Rating Backed by Positive Clinical Data and Market Potential for ZP Treatment
Bicycle Therapeutics Grants 73,700 Share Options To Eight New Employees Under 2024 Inducement Plan
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Companies Like Bicycle Therapeutics (NASDAQ:BCYC) Are In A Position To Invest In Growth
Eckert & Ziegler Enters Strategic Partnership With Bicycle Therapeutics For Radioisotope Supply And Contract Development And Manufacturing Of Bicycle Radio Conjugates